Drug intelligence / Profile preview

tetanus toxoid reduced diphtheria toxoid acellular pertussis-Sanofi Pasteur, a Sanofi Company-dengue

Development stage: Approved
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

tetanus toxoid reduced diphtheria toxoid acellular pertussis-Sanofi Pasteur, a Sanofi Company-dengue refers to the co-administration or combined study of Sanofi Pasteur's Tdap vaccine (Adacel) and its tetravalent dengue vaccine (Dengvaxia/CYD-TDV). Adacel is a sterile isotonic suspension of tetanus and diphtheria toxoids and adsorbed acellular pertussis antigens, used for booster immunization. Dengvaxia is a live-attenuated chimeric vaccine using a yellow fever 17D virus backbone to express the pre-membrane and envelope proteins of the four dengue virus serotypes (DENV-1, 2, 3, and 4). This combination was specifically evaluated in Phase 2 clinical trials (such as NCT00842530) to determine the safety and immunogenicity of simultaneous or sequential administration in pediatric populations in endemic regions.

Brand names: AdacelDengvaxia
Other names: Adacel + DengvaxiaTdap + CYD-TDVCYD Dengue Vaccine + Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis

Beyond the preview

Go deeper on tetanus toxoid reduced diphtheria toxoid acellular pertussis-Sanofi Pasteur, a Sanofi Company-dengue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus toxoid reduced diphtheria toxoid acellular pertussis-Sanofi Pasteur, a Sanofi Company-dengue.

Explore the full profile